A model of care for familial hypercholesterolaemia: Key role for clinical biochemistry

Clinical Biochemist Reviews

Volumn 33, Issue 1, 2012, Pages 25-31

  Watts, Gerald F ^a   Sullivan, David R ^b   van Bockxmeer, Frank M ^c   Poplawski, Nicola ^d   Hamilton Craig, Ian ^e   Clifton, Peter M ^f   O'Brien, Richard C ^g   George, Peter M ^h   Burnett, John R ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^e GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^f BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859741457     PISSN: 01598090     EISSN: 18380212     Source Type: Journal    
DOI: None     Document Type: Note

References (33)

1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160:407-20.
2. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004;160:421-9.
3. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1-14.
4. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky A. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52: 1544-68.
5. Bates TR, Burnett JR, van Bockxmeer FM, Hamilton S, Arnolda L, Watts GF. Detection of familial hypercholesterolaemia: a major treatment gap in preventative cardiology. Heart Lung Circ 2008;17:411-3.
6. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007;4:214-25.
7. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost-effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002;324:1303.
8. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
9. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008;29:2625-33.
10. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124:2202-7.
11. Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000;321:148.
12. Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010;209:189-94.
13. National Institute for Health and Clinical Excellence, The National Collaborating Centre for Primary Care. NICE clinical guideline 71: Identification and management of familial hypercholesterolaemia. 2008. http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuideline.pdf (Accessed 4 January 2012).
14. Civeira F International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68.
15. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:133-40.
16. Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011;218:272-80.
17. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, et al. Familial hypercholesterolaemia: A model of care for Australasia. Atheroscler Suppl 2011;12:221-63.
18. Thompson GR HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198:247-55.
19. Humphries S. Guidelines for the identification and management of patients with familial hypercholesterolaemia (FH): Are we coming to a consensus? Atheroscler Suppl 2011;12:217-20.
20. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171-6.
21. World Health Organization. Familial hypercholesterolaemia. Report of a second WHO consultation. Geneva: World Health Organization; 1999.
22. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
23. Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol 2008;19:362-8.
24. Burton H, Alberg C, Stewart A. Heart to heart: Inherited Cardiovascular Conditions Services. A needs assessment and service review. PHG Foundation; 2009. http://www.phgfoundation.org/reports/4986/ (Accessed 4 January 2012).
25. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010;122:2748-64.
26. Robinson JG, Goldberg AC National Lipid Association Expert Panel on Familial Hypercholesterolemia. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S18-29.
27. Thorogood M, Seed M, De Mott K Guideline Development Group. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG 2009;116:478-9.
28. Appleton CA, Caldwell G, McNeil A, Meerkin M, Sikaris K, Sullivan DR, et al Australian Pathology Lipid Interest Group. Recommendations for lipid testing and reporting by Australian pathology laboratories. Clin Biochem Rev 2007;28:32-45.
29. Lau JF, Smith DA. Advanced lipoprotein testing: recommendations based on current evidence. Endocrinol Metab Clin North Am 2009;38:1-31.
30. Datta BN, McDowell IF, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol 2010;21: 366-71.
31. Shenkin PA. Training in metabolic medicine. Clin Med 2001;1:392.
32. Pedersen KMV, Humphries SE, Roughton M, Besford JS. National Clinical Audit of the Management of Familial Hypercholesterolaemia 2010: Full Report. Clinical Standards Department, Royal College of Physicians, December 2010. http://www.rcplondon.ac.uk/resources/audits/FH (Accessed 4 January 2012).
33. Aarden E, Van Hoyweghen I, Horstman K. The paradox of public health genomics: definition and diagnosis of familial hypercholesterolaemia in three European countries. Scand J Public Health 2011;39:634-9.